This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics US
December 15 - 18, 2024
Marriott Marquis San DiegoLive In-Person Event: December 15 - 18, 2024

Chengcheng (Alec) Zhang, Ph.D.
Professor, Department of Physiology at UT Southwestern Medical Center


Dr. Chengcheng (Alec) Zhang, Morton H. Sanger Professorship in Oncology and Michael L. Rosenberg Scholar for Biomedical Research at University of Texas Southwestern Medical Center, earned his B.S. degree from University of Science and Technology of China in 1992 and his Ph.D. in Biochemistry from the University of Illinois at Urbana-Champaign in 1999. He received his postdoctoral training under the mentorship of Dr. Harvey Lodish at Whitehead Institute/MIT, where he initiated several projects on hematopoietic stem cells and cancer research. Dr. Zhang established his independent lab at UT Southwestern Medical Center in 2007.

His laboratory research focuses on the biology of immune inhibitory receptors including leukocyte Ig-like receptor subfamily B (LILRB) in cancer immunology and hematopoietic cells. He is also accustomed to working at the intersection of basic research and its clinical applications; anti-LILRB2 and anti-LILRB4 blocking antibodies discovered by his team/collaborators are in clinical trials for treatment of myeloid leukemia and solid cancers. He published 114 peer-reviewed publications in hematopoietic and cancer research fields. He was a recipient of several awards, including American Society of Hematology Junior Faculty Scholar Award, Leukemia & Lymphoma Society Scholar Award, and Royan International Research Award. He has trained 8 graduate students and 27 post-doctoral researchers. Many of his former postdoc trainees acquired faculty positions.

Agenda Sessions

  • LILRBs - Myeloid Checkpoint Targets for Cancer Treatment